|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
134,986 |
251,929 |
319,053 |
656,089 |
Total Sell Value |
$11,097,511 |
$21,508,551 |
$27,661,182 |
$61,420,002 |
Total People Sold |
5 |
6 |
7 |
7 |
Total Sell Transactions |
9 |
19 |
27 |
56 |
End Date |
2024-04-04 |
2024-01-02 |
2023-07-04 |
2022-07-04 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-11 |
4 |
AS |
$89.84 |
$359,360 |
D/D |
(4,000) |
170,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-11 |
4 |
OE |
$17.33 |
$69,320 |
D/D |
4,000 |
174,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-10 |
4 |
AS |
$91.31 |
$365,240 |
D/D |
(4,000) |
170,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-10 |
4 |
OE |
$17.33 |
$69,320 |
D/D |
4,000 |
174,682 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2017-01-09 |
4 |
AS |
$90.00 |
$450,000 |
D/D |
(5,000) |
18,100 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-09 |
4 |
AS |
$89.79 |
$359,160 |
D/D |
(4,000) |
170,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-09 |
4 |
OE |
$17.33 |
$69,320 |
D/D |
4,000 |
174,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-06 |
4 |
AS |
$87.19 |
$348,760 |
D/D |
(4,000) |
170,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2017-01-06 |
4 |
OE |
$17.33 |
$69,320 |
D/D |
4,000 |
174,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2016-12-30 |
4 |
AS |
$83.35 |
$333,400 |
D/D |
(4,000) |
170,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2016-12-30 |
4 |
OE |
$17.33 |
$69,320 |
D/D |
4,000 |
174,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2016-12-29 |
4 |
AS |
$83.84 |
$335,360 |
D/D |
(4,000) |
170,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2016-12-29 |
4 |
OE |
$17.33 |
$69,320 |
D/D |
4,000 |
174,682 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2016-11-25 |
4 |
AS |
$87.40 |
$1,310,988 |
D/D |
(15,000) |
113,878 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2016-11-25 |
4 |
OE |
$26.49 |
$397,350 |
D/D |
15,000 |
128,878 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2016-11-22 |
4 |
AS |
$85.69 |
$5,976,515 |
D/D |
(69,743) |
170,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2016-11-22 |
4 |
OE |
$26.49 |
$1,847,492 |
D/D |
69,743 |
240,425 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2016-11-21 |
4 |
AS |
$87.56 |
$6,106,478 |
D/D |
(69,744) |
170,682 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2016-11-21 |
4 |
OE |
$26.49 |
$1,847,519 |
D/D |
69,744 |
240,426 |
|
- |
|
Davis George Eric |
EVP, General Counsel |
|
2016-11-18 |
4 |
AS |
$90.42 |
$452,100 |
D/D |
(5,000) |
70,798 |
|
- |
|
Davis George Eric |
EVP, General Counsel |
|
2016-11-18 |
4 |
OE |
$38.59 |
$192,950 |
D/D |
5,000 |
75,798 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2016-11-16 |
4 |
AS |
$90.97 |
$3,790,795 |
D/D |
(41,670) |
323,368 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2016-11-16 |
4 |
OE |
$17.54 |
$730,892 |
D/D |
41,670 |
365,038 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2016-11-09 |
4 |
S |
$90.61 |
$1,812,206 |
D/D |
(20,000) |
23,100 |
|
- |
|
Lawlis V Bryan |
Director |
|
2016-11-09 |
4 |
AS |
$95.00 |
$712,500 |
D/D |
(7,500) |
13,860 |
|
- |
|
1285 Records found
|
|
Page 38 of 52 |
|
|